A Phase 2 interventional study of ATX-101 and ATX-101 in Acute Postoperative Pain, sponsored by Allay Therapeutics, Inc.. Terminated at 13 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Allay Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Pain, Postoperative with a site in United Kingdom — 6 open to participants now, 6 under way, 1 of them phase 3. Pain, Postoperative · United Kingdom.
Among the 51 studies in Pain, Postoperative with a site in United Kingdom, this one is the 17th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 43rd registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →6 of the 51 studies in Pain, Postoperative with a site in United Kingdom are open now. Recruiting first, the newest first:
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18–75 · Men only
University of Aberdeen · Sites in United Kingdom, Croatia
Ages 18+
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Monash University · Sites in United Kingdom, Australia, Hong Kong and 1 more country
Ages 18+ · Women only
Queen Mary University of London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 100 across the 40 interventional studies, 200 across the 11 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 51 have an industry lead sponsor. The 10 most frequent:
Allay Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Allay Therapeutics, Inc. has 2 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
1 of the studies in Pain, Postoperative with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06275698East and North Hertfordshire NHS TrustHONEY for the Treatment of POst-Tonsillectomy Pain | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies in Pain, Postoperative with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2B randomized, double blind, active controlled, multi-center clinical trial to evaluate the safety and efficacy of ATX-101 in participants following total knee arthroplasty. The following is short title and acronym for the study: Study Assessing Pain Relief after Replacement of the Knee (SPARK)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ATX-101 Dose A
Drug: ATX-101
ATX-101 Dose B
Drug: ATX-101
bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block
Drug: bupivacaine hydrochloride without epinephrine
ATX-101 (bupivacaine) implant, one-time administration into the surgical site
ATX-101 (bupivacaine) implant, one-time administration into the surgical site
bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
Area Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity.
NRS-R for pain intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: from 30 minutes post-surgery through hour 168 (Day 8)
Percentage of Subject Who Remain Opioid Free.
Opioid free is defined as no opioid rescue medication was recorded for the timepoint displayed and onwards.
Time frame: Surgical Closure to Day 30
Total Post-surgical Use of Rescue Opioid Medications.
Total post-surgical use of rescue opioid medications (days).
Time frame: Surgical Closure to Day 30, Opioid consumption is summarized descriptively every 24-hour period through Day 30
Time to First Rescue Opioid Medication.
Time to first postsurgical use of rescue opioid medication (days).
Time frame: Surgical Closure to Day 30
| Milestone | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| Started | 37 | 37 | 34 | 4 |
| Completed | 37 | 36 | 34 | 4 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
NRS-R for pain intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| pain intensity score*hour | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| Area Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity. | 517.32 ± 284.675 | 518.03 ± 239.299 | 595.26 ± 258.945 | 756.84 ± 261.454 |
Opioid free is defined as no opioid rescue medication was recorded for the timepoint displayed and onwards.
| Participants | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| Surgical Closure - Day 30 | 3 | 6 | 1 | 0 |
| Day 4 - Day 30 | 12 | 13 | 6 | 0 |
| Day 5 - Day 30 | 13 | 15 | 6 | 0 |
| Day 8 - Day 30 | 14 | 17 | 10 | 1 |
| Day 15 - Day 30 | 17 | 22 | 16 | 1 |
| Day 22 - Day 30 | 24 | 27 | 23 | 1 |
Total post-surgical use of rescue opioid medications (days).
| IV Morphine Milligram Equivalent (MME) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| Surgical Closure - Hour 24 (Day 1) | 63.153 ± 62.6833 | 58.399 ± 47.1712 | 43.283 ± 29.0513 | 119.800 ± 58.1316 |
| Hour 24 (Day 1) - Hour 48 (Day 2) | 44.628 ± 40.0835 | 33.566 ± 29.9608 | 36.804 ± 30.9289 | 107.250 ± 50.5486 |
| Hour 48 (Day 2) - Hour 72 (Day 3) | 30.500 ± 25.1244 | 25.795 ± 18.9251 | 32.550 ± 21.3338 | 40.000 ± 8.6603 |
| Hour 72 (Day 3) - Day 4 | 24.044 ± 22.3062 | 23.783 ± 19.7504 | 25.369 ± 16.9465 | 35.000 ± 22.9129 |
| Day 4 - Day 5 | 26.733 ± 26.0054 | 22.214 ± 18.1274 | 23.853 ± 20.0357 | 37.500 ± 19.8431 |
| Day 5 - Day 6 | 25.000 ± 21.5058 | 24.063 ± 22.5092 | 25.067 ± 25.0933 | 40.000 ± 22.9129 |
| Day 6 - Day 7 | 27.206 ± 21.8818 | 18.923 ± 13.2725 | 26.225 ± 21.1209 | 27.500 ± 15.6125 |
| Day 7 - Day 8 | 19.147 ± 13.7509 | 16.000 ± 9.7033 | 28.219 ± 20.8734 | 18.750 ± 9.9216 |
| Day 8 - Day 9 | 19.147 ± 10.3089 | 21.042 ± 17.0140 | 19.833 ± 13.7369 | 25.000 ± 17.3205 |
| Day 9 - Day 10 | 20.176 ± 13.4768 | 15.045 ± 8.3260 | 20.192 ± 13.8241 | 20.000 ± 11.4564 |
| Day 10 - Day 11 | 20.214 ± 12.4216 | 17.591 ± 10.9654 | 21.100 ± 13.8824 | 12.750 ± 3.1820 |
| Day 11 - Day 12 | 16.417 ± 12.7201 | 14.208 ± 11.3367 | 15.875 ± 8.0770 | 15.000 ± 7.5000 |
| Day 12 - Day 13 | 16.071 ± 10.7289 | 15.900 ± 9.1767 | 21.567 ± 14.9354 | 12.500 ± 4.3301 |
| Day 13 - Day 14 | 13.571 ± 7.1195 | 14.591 ± 7.5459 | 19.500 ± 12.8504 | 30.000 ± NA |
| Day 14 - Day 15 | 20.200 ± 17.2293 | 13.850 ± 9.6149 | 14.091 ± 6.5453 | 15.000 ± 10.6066 |
| Day 15 - Day 16 | 17.045 ± 11.6092 | 17.571 ± 7.7051 | 12.321 ± 8.5605 | 15.000 ± 10.6066 |
| Day 16 - Day 17 | 14.821 ± 7.8117 | 11.167 ± 4.1307 | 18.682 ± 10.6941 | 15.000 ± 10.6066 |
| Day 17 - Day 18 | 14.271 ± 8.7331 | 12.700 ± 5.7359 | 10.232 ± 8.8154 | 15.000 ± 10.6066 |
| Day 18 - Day 19 | 17.981 ± 20.5113 | 12.500 ± 6.1237 | 11.411 ± 9.1744 | 7.500 ± 0.0000 |
| Day 19 - Day 20 | 17.550 ± 14.2993 | 7.875 ± 0.7500 | 14.722 ± 10.1122 | 11.250 ± 5.3033 |
| Day 20 - Day 21 | 17.778 ± 15.1783 | 13.000 ± 9.5481 | 12.563 ± 5.2809 | 7.500 ± 0.0000 |
| Day 21 - Day 22 | 17.273 ± 14.3267 | 11.083 ± 5.5083 | 10.972 ± 4.9124 | 7.500 ± 0.0000 |
| Day 22 - Day 23 | 19.861 ± 17.0069 | 9.750 ± 3.5707 | 13.750 ± 5.6458 | 18.333 ± 18.7639 |
| Day 23 - Day 24 | 16.750 ± 14.1323 | 11.000 ± 4.1683 | 11.250 ± 4.1079 | 31.667 ± 41.8579 |
| Day 24 - Day 25 | 13.906 ± 14.7515 | 13.400 ± 11.0872 | 13.750 ± 3.0619 | 18.333 ± 18.7639 |
| Day 25 - Day 26 | 18.750 ± 14.2705 | 12.357 ± 9.0725 | 13.500 ± 3.3541 | 7.500 ± 0.0000 |
| Day 26 - Day 27 | 9.844 ± 6.1397 | 9.857 ± 3.8699 | 11.250 ± 7.5000 | 23.750 ± 22.9810 |
| Day 27 - Day 28 | 18.500 ± 20.6610 | 12.700 ± 6.9964 | 10.000 ± 4.3301 | — |
| Day 28 - Day 29 | 17.917 ± 19.1974 | 11.700 ± 5.9224 | 6.563 ± 1.8750 | 20.000 ± NA |
| Day 29 - Day 30 | 47.500 ± NA | 16.000 ± NA | 7.500 ± 0.0000 | — |
Time to first postsurgical use of rescue opioid medication (days).
| Days | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| Time to First Rescue Opioid Medication. | 0.478 ± 0.9862 | 0.257 ± 0.2571 | 0.491 ± 0.6925 | 0.223 ± 0.0820 |
Collected over Day 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATX-101 1000 mg | 0/37 (0%) | 3/37 (8.1%) | 30/37 (81.1%) |
| ATX-101 1500 mg | 0/37 (0%) | 4/37 (10.8%) | 25/37 (67.6%) |
| Bupivacaine Hydrochloride | 0/34 (0%) | 2/34 (5.9%) | 28/34 (82.4%) |
| Saline Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/37 | 0/37 | 1/34 | 0/4 |
| Pulmonary embolismVascular disorders | 0/37 | 1/37 | 1/34 | 0/4 |
| Atrial fibrillationCardiac disorders | 1/37 | 0/37 | 0/34 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/37 | 1/37 | 0/34 | 0/4 |
| Duodenal ulcerGastrointestinal disorders | 1/37 | 0/37 | 0/34 | 0/4 |
| Liver injuryHepatobiliary disorders | 0/37 | 1/37 | 0/34 | 0/4 |
| Incision site dischargeInjury, poisoning and procedural complications | 1/37 | 0/37 | 0/34 | 0/4 |
| Hepatic enzyme increasedInvestigations | 0/37 | 1/37 | 0/34 | 0/4 |
| DeliriumPsychiatric disorders | 0/37 | 1/37 | 0/34 | 0/4 |
| Event | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 11/37 | 10/37 | 9/34 | 2/4 |
| ConstipationGastrointestinal disorders | 5/37 | 4/37 | 9/34 | 1/4 |
| Joint swellingMusculoskeletal and connective tissue disorders | 1/37 | 2/37 | 4/34 | 1/4 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/37 | 2/37 | 1/34 | 1/4 |
| DizzinessNervous system disorders | 3/37 | 6/37 | 0/34 | 0/4 |
| Procedural painInjury, poisoning and procedural complications | 2/37 | 4/37 | 5/34 | 0/4 |
| ContusionInjury, poisoning and procedural complications | 3/37 | 2/37 | 4/34 | 0/4 |
| VomitingGastrointestinal disorders | 3/37 | 0/37 | 4/34 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/37 | 1/37 | 2/34 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 3/37 | 2/37 | 1/34 | 0/4 |
| Age, Categorical(Participants) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 15 | 14 | 2 | 46 |
| >=65 years | 22 | 22 | 20 | 2 | 66 |
| Age, Continuous(years) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| Mean | 68.2 ± 8.12 | 68.3 ± 6.89 | 67.5 ± 7.62 | 63.0 ± 12.38 | 67.8 ± 7.69 |
| Sex: Female, Male(Participants) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| Female | 20 | 19 | 22 | 2 | 63 |
| Male | 17 | 18 | 12 | 2 | 49 |
| Race/Ethnicity, Customized(Participants) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 3 | 1 | 0 | 4 |
| Black or African American | 0 | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 35 | 31 | 32 | 4 | 102 |
| Other | 2 | 1 | 0 | 0 | 3 |
| Unknown | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| Canada | 7 | 6 | 7 | 0 | 20 |
| United Kingdom | 10 | 10 | 13 | 0 | 33 |
| Australia | 20 | 21 | 14 | 4 | 59 |
| Body Mass Index (BMI)(kg/m2) | ATX-101 1000 mg | ATX-101 1500 mg | Bupivacaine Hydrochloride | Saline Placebo | Total |
|---|---|---|---|---|---|
| Mean | 30.39 ± 4.473 | 31.20 ± 5.131 | 33.01 ± 5.185 | 29.58 ± 1.431 | 31.42 ± 4.934 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Jan 2024, 19 months.
Results were first posted in Aug 2025, 1 year 6 months after primary completion. A results delay was requested in Dec 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101
Allay Therapeutics, Inc.